Updates to the 2007 NAEPP/NHLBI asthma guidelines were published in late 2020. These updates cover five specific areas of asthma evaluation and management but leave many areas without updates. To fill in those gaps, many clinicians use the GINA guidelines produced in the UK. In this presentation, the new NAEPP/NHLBI updates will be reviewed and compared to older recommendations and to the broader recommendations from GINA. By including both sets of guidelines, the full spectrum of asthma diagnosis, evaluation and management can be reviewed.
Credits: 1.50 contact hours; 1.25 are pharmacology
Release Date: July 10, 2021
End Date: July 10, 2022
After taking part in this educational activity, participants should be better able to:
- Incorporate the 2020 NAEPP updates to the 2007 asthma guidelines.
- Compare recommendations from 2020 NAEPP with the broader international GINA asthma guidelines.
- Incorporate tools into practice that support guideline-concordant asthma care.
Barbara P. Yawn, MD, MSc, MSPH, FAAFP
University of Minnesota Family and Community Health
Barbara P. Yawn, MD, MS, MSc, is the Chief Science Officer of the COPD Foundation, a national COPD educational and advocacy organization. She also serves as an Adjunct Professor in the Department of Family and Community Health at the University of Minnesota School of Medicine, and in the Department of Family Medicine at the University of South Dakota Medical School.
Dr. Yawn is a longstanding member of numerous professional societies and committees. She has contributed to 15 practice guidelines, including the WHO international asthma symptoms-based guidelines (IPAG) and the NHLBI 2007 Asthma Guidelines update. She has published over 400 articles in peer-reviewed journals, including approximately 70 articles on asthma and COPD. She has presented over 1000 professional papers and talks.
Dr. Yawn is Editor-in-Chief of Respiratory Medicine Case Reports and Section Editor for Respiratory Medicine and the Mayo Clinic Proceedings. She has served on the Editorial Boards of The Journal of Family Practice, Journal of Asthma and Allergy, Journal of International Respiratory Group, and Allergy Management in Practice, among other journals. Before joining the COPD Foundation, Dr. Yawn spent 20 years as founder and director of the Olmsted Medical Center and HealthSystem’s department of clinical research after completing 15 years of rural primary care practice.
Obtain Your Credits
To earn credits for this activity, you must complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile dashboard transcript for future access.
NPACE designates this educational activity for a maximum of 1.50 contact hours, of which 1.25 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Associates for Continuing Education (NPACE) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720 and Florida CE Broker #50-1476.
Contributing faculty, Barbara P. Yawn, MD, MSc, MSPH, FAAFP, have disclosed the following relevant financial relationship: Consultant and Advisor for Astra Zeneca; Consultant for American Academy of Family Physicians, BI, and GSK.
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There is no commercial support for this activity.
|Access Date||Quiz Result||Score||Actions|